Clinical Trials

Breast Neoplasms

NCT04920708 2026-04-14

FAIM

57 enrolled

Breast Neoplasms

NCT07164976 2026-04-13

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

Phase 1/2 Recruiting

86 enrolled

Breast Neoplasms

NCT07487129 2026-03-23

Clinical and P

Phase 4 Completed

206 enrolled

Breast Neoplasms

NCT06377852 2026-03-18

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Phase 3 Recruiting

500 enrolled

Breast Neoplasms

NCT07237256 2026-03-16

NoLEEta

Phase 3 Recruiting

3,902 enrolled

Breast Neoplasms

NCT02712723 2026-03-11

FELINE

121 enrolled 9 charts

Breast Neoplasms

NCT06585969 2026-02-12

DISCORDANT

Phase 3 Withdrawn

Breast Neoplasms

NCT05996107 2026-01-28

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer

Phase 1 Recruiting

30 enrolled

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT03285412 2025-12-22

LEADER

120 enrolled

Breast Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

15 enrolled

Breast Neoplasms

NCT06062498 2025-10-20

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

174 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07195227 2025-10-02

CADILLAC

150 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT02608216 2025-09-03

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

20 enrolled

Breast Neoplasms

NCT05900206 2025-09-02

ARIADNE

370 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT04055493 2025-08-26

ADAPTcycle

1,684 enrolled

Breast Neoplasms

NCT05625087 2025-08-20

SAFIR 03

162 enrolled

BreastClassical hematology

Breast Neoplasms

NCT07008508 2025-06-06

BRAVE-Cyclin

Active not recruiting

300 enrolled

Breast Neoplasms, Cardiovascular Diseases, Venous Thromboembolism

NCT03294694 2025-05-31

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Phase 1 Terminated

33 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms

NCT05207709 2025-04-29

HARMONIA

Phase 3 Active not recruiting

456 enrolled

Breast Neoplasms

NCT04315233 2025-04-22

CHARGE

Phase 1 Recruiting

34 enrolled

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT05296746 2025-03-18

RIBOLARIS

1,100 enrolled

Breast Neoplasms

NCT05816655 2025-03-18

Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

202 enrolled

Phase NA Not yet recruiting

Breast Neoplasms

NCT06810492 2025-03-17

The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment

40 enrolled

Breast Neoplasms

NCT03944434 2025-02-26

FACILE

116 enrolled

Breast Neoplasms

NCT06805812 2025-02-03

PALMARES-2

Recruiting

3,500 enrolled

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

NCT04256941 2024-12-27

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Phase 2 Terminated

4 enrolled 7 charts

Breast Neoplasms

NCT02632045 2024-12-06

MAINTAIN

169 enrolled 12 charts

Breast Neoplasms

NCT04657679 2024-11-26

LEANORA

Phase 4 Terminated

21 enrolled 19 charts

Breast Neoplasms

NCT06587789 2024-11-21

Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer

Recruiting

286 enrolled

Breast Neoplasms

NCT03956654 2024-08-09

RibOB

Completed

78 enrolled

Breast Neoplasms

NCT05163106 2024-08-02

NEOLETRIB

85 enrolled

Breast Neoplasms

NCT02035813 2024-06-04

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

116 enrolled

Phase 3 Active not recruiting

Breast Neoplasms, Neoplastic Cells, Circulating

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

271 enrolled

Breast Neoplasms

NCT05452213 2023-04-18

CAPTOR-BC

Phase 4 Recruiting

1,000 enrolled

Breast Neoplasms

NCT05766410 2023-03-16

ORACLE-RIPA

60 enrolled

Breast Neoplasms

NCT02657343 2022-08-01

An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

Phase 1/2 Completed

25 enrolled 16 charts

Breast Neoplasms

NCT03913234 2022-05-10

Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients

Phase 1/2 Unknown

95 enrolled

Breast Neoplasms

NCT02586675 2022-01-21

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

Phase 1 Completed

7 enrolled 8 charts

Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

NCT04585724 2021-10-18

Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases

Phase 1 Withdrawn

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03905343 2021-06-16

Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC

Phase 3 Terminated

25 enrolled

Breast Neoplasms

NCT04852081 2021-04-21

Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.

Unknown

1,000 enrolled

Breast Neoplasms

NCT03248427 2021-03-17

CORALLEEN

106 enrolled